Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in NSCLC patients failing erlotinib or gefitinib
NCT00656136Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Apr 2008; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00656136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00656136.